Drug Clinical Trials List

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease	Agios Pharmaceuticals, Inc.	Ongoing	Mitapivat	2/3	AG348-C-020	King Khalid University Hospital (Riyadh)
Prospective, observational study in sickle cell disease patients on crizanlizumab treatment in Middle East countries and India.	Novartis	Ongoing	crizanlizumab	4	CSEG101AIC05	Prince Mohammad Bin Naser Hospital, Jizan, Saudi Arabia
A PHASE II, SINGLE-ARM STUDY OF ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER WHO HAVE NOT PROGRESSED AFTER PLATINUM-BASED CONCURRENT CHEMORADIATION	Roche	Ongoing	ATEZOLIZUMAB (TECENTRIQ)	2	MO43156	King Fahad Specialist Hospital (Dammam)
A randomized, sham-controlled, double-blind study to evaluate the efficacy and safety of intrathecal (IT) OAV101 in patients with later onset Type 2 spinal muscular atrophy (SMA) who are ≥ 2 to < 18 years of age, treatment naive, sitting, and never ambulatory	Novartis Saudi Limited	Ongoing	OAV101 (formerly AVXS-101)	3	COAV101B12301	King Faisal Specialist Hospital and Research Center (Riyadh),King Fahad Specialist Hospital (Dammam)
Timing Of Thyroxine Dose In Ramadan	KAIMRC	Ongoing	Levothyroxine	4	ICT22J/001	King Abdulaziz Medical City NG (Jeddah)
Fluids in septic shock (FISSH)	KAIMRC	Ongoing	RINGER'S-LACTATE SOLUTION	3	SCT21R/001/01	King Abdulaziz Medical City NG (Riyadh)
Phase II study of neoadjuvant hormonal therapy guided by interval Ki67 testing in hormonal receptor-positive, HER2-negative breast cancer.	King Abdullah Medical City (Makkah)	Ongoing	Letrozole (Femaplex)	2	20-718	King Abdullah Medical City (Makkah)
Modern Treatment of Inhibitor-PositiVe PATiEnts with Haemophilia A – An International Low-Interventional Pragmatic Investigator Initiated Trial	Octapharma AG	Ongoing	Octanate, Wilate, Hemlibra, NovoSeven, Feiba	4	MOTIVATE	King Abdulaziz Medical City NG (Riyadh)
Phase 1b/2 Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia	Onyx Therapeutics, Inc., an Amgen Inc. Subsidiary	Ongoing	Carfilzomib	2	20140106	King Fahad Medical City (Riyadh)
The Effectiveness of Sixteen Milligrams of Dexamethasone in Preventing Postoperative Nausea and Vomiting After Cesarean Delivery Under Neuroaxial Anesthesia	King Khalid University Hospital	Rejected	Dexamethasone sodium phosphate	4	E-21-6388	King Khalid University Hospital (Riyadh)